Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275

Benzinga Newsdesk www.benzinga.com Positive 67.1%

Neg 0% Neu 0% Pos 67.1%

Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.